ArticleJournal of animal science and biotechnology2025
Lactate alleviates intestinal barrier injury in weaned piglets via activation of the Wnt/β-catenin pathway and promotion of intestinal epithelial cell proliferation.
Article in Journal of animal science and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundInflammatory bowel disease causes intestinal structural damage, impairs gut function, hinders animal growth and development, and reduces farming efficiency. Previous studies demonstrated that lactate alleviates dextran sulfate sodium (DSS)-induced inflammation and mitigates weight loss by enhancing intestinal barrier functions. However, the mechanisms underlying lactate-mediated protection of the intestinal epithelial barrier remain unclear. This study aimed to explore the protective effect of lactate on intestinal barrier damage in colitis piglets and the possible underlying mechanisms through in vivo and in vitro experiments.
methodsA total of 60 21-day-old weaned female piglets were randomly assigned into three groups based on weight: the control group (basal diet with physiological saline gavage), the DSS group (basal diet with 5% DSS gavage), and the DSS + LA group (2% lactate diet with 5% DSS gavage). There were 10 replicates per treatment, with 2 piglets per replicate. Jejunal morphology was assessed via hematoxylin and eosin staining, while Western blotting quantified the protein levels of proliferation markers, including cluster of differentiation 24 (CD24), cyclin D1, and wingless/integrated (Wnt)/β-catenin signaling components. In vitro, 0.08% DSS and 2-32 mmol/L sodium lactate-treated intestinal porcine epithelial cell line-J2 (IPEC-J2) cells (n = 4) were assessed for viability (Cell Counting Kit-8 assay), apoptosis (flow cytometry), and proliferation parameters, including cell cycle analysis and Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5
resultsIn vivo, DSS administration induced jejunal villus shortening (P < 0.05), downregulated protein levels of CD24, cyclin D1, casein kinase 1 (CK1), and dishevelled-2 (DVL2) (P < 0.05). In vitro, DSS promoted apoptosis, inhibited proliferation, diminished the Lgr5
conclusionsIn summary, lactate ameliorated intestinal barrier damage in DSS-induced colitis by activating the Wnt/β-catenin pathway and restoring the balance between epithelial cell proliferation and apoptosis. This study provides novel mechanistic evidence supporting lactate's therapeutic potential for IBD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.